scholarly journals The American Academy of Oral Medicine clinical practice statement: dental care for the patient on antiresorptive drug therapy

2019 ◽  
Vol 127 (2) ◽  
pp. 136-139
Author(s):  
Juan M. Bugueno ◽  
Cesar A. Migliorati
2021 ◽  
pp. 238008442110003
Author(s):  
T.M. Nguyen ◽  
U. Tonmukayakul ◽  
H. Calache

The coronavirus disease 2019 (COVID-19) has disrupted essential oral healthcare in Australia. Sources for COVID-19 transmission via dental settings is considered to have high potential due to the production of aerosols and because transmission can occur through the airborne route. However, COVID-19 cases in dentistry is reportedly low. Delayed timely dental care, where severe oral diseases remain undetected, untreated, or asymptomatic such as advanced dental caries, periodontitis, and head and neck cancer, can have detrimental consequences for individuals at increased risk for oral diseases. The dental profession should remain vigilant and advocate for the continuation of essential oral healthcare even in times of uncertainty. Knowledge Transfer Statement: The reportedly low COVID-19 transmission occurring in dental settings highlight achievements made by the dental profession. There are valid reasons to reconsider risk-based essential oral healthcare during the COVID-19 pandemic.


2019 ◽  
Vol 23 (4) ◽  
Author(s):  
Anna Wierzbicka-Rot ◽  
Artur Gadomski

In February 2019 American Academy of Otolaryngology-Head and Neck Surgery published clinical practice guidelines which provides evidence-based recommendations that applies to children under consideration for tonsillectomy. This update to the 2011 publication includes large amount of new, practical information about pre-, intra- and postoperative care and management, that can be useful for surgeons as well as GPs and pediatricians


2019 ◽  
Vol 161 (1) ◽  
pp. 3-5
Author(s):  
Andrés M. Bur ◽  
Richard M. Rosenfeld

Clinical practice guidelines (CPGs), developed to inform clinicians, patients, and policy makers about what constitutes optimal clinical care, are one way of increasing implementation of evidence into clinical practice. Many factors must be considered by multidisciplinary guideline panels, including strength of available evidence, limitations of current knowledge, risks/benefits of interventions, patient values, and limited resources. Grading of Recommendations Assessment, Development and Evaluation (GRADE) is a framework for summarizing evidence that has been endorsed by many national and international organizations for developing CPGs. But is GRADE the right choice for CPGs developed by the American Academy of Otolaryngology–Head and Neck Surgery Foundation (AAO-HNSF)? In this commentary, we will introduce GRADE, discuss its strengths and limitations, and address the question of what potential benefits GRADE might offer beyond existing methodology used by the AAO-HNSF in developing CPGs.


2018 ◽  
Author(s):  

Keep current with the latest clinical practice guidelines and policies from the American Academy of Pediatrics covering more than 40 clinical practice guidelines, plus every AAP policy statement, clinical report, and technical report through December 2017.


2011 ◽  
Vol 93 (2) ◽  
pp. 203-205 ◽  
Author(s):  
Rolando Izquierdo ◽  
Ilya Voloshin ◽  
Sara Edwards ◽  
Michael Q Freehill ◽  
Walter Stanwood ◽  
...  

2018 ◽  
pp. 96-102
Author(s):  
Julia C. Stingl ◽  
Gonzalo Laje

Molecular medicine has opened new possibilities of personalized approaches in drug therapy. The development of evidence-based pharmacogenetic guidelines to steer therapy has slowly entered the field of psychiatric therapeutics. Some of the reasons behind the limited progress in psychiatric pharmacogenomics include the broad definition of clinical syndromes, limited knowledge of psychiatric pathophysiology, and limited understanding of psychotropics’ mechanisms of action. Pharmacogenomic markers have been reported for both pharmacodynamic and pharmacokinetic genes. However, only genetic variation in pharmacokinetic genes has shown to be helpful in clinical practice. There is little consensus as to when and if pharmacogenetic tests should be used in psychiatry. There are limited evidence-based dosing guidelines available for actionable gene–drug pairs. Future work in psychiatry may deepen our understanding of the biological underpinnings of psychiatric syndromes and provide the potential for individual tailored therapies.


Sign in / Sign up

Export Citation Format

Share Document